HHS & Healthcare Contracts Intelligence — August 08, 2026

Westat won a cost-plus-fixed-fee contract for the PATH study, providing a low-risk revenue stream with a potential total value of $780.5 million through 2036, signaling strong competitive positioning in health R&D services.

The contract's massive potential value ($780.5M) is contingent on NIH exercising all options, which depends on future federal budget allocations for health research. A Continuing Resolution (CR) or budget cuts could delay or cancel option periods.

The contract's potential 12-year lifespan (through 2036) provides a platform for Westat to expand its capabilities in longitudinal health studies, potentially leading to follow-on work with NIH or other HHS agencies.

The $85.5M PATH study contract demonstrates sustained government commitment to long-term population health research, providing predictable revenue for specialized contractors like Westat.

{"entity" => "Westat, Inc.", "reason" => "The company's revenue visibility is heavily tied to the exercise of options on this $85.5M contract, which could add up to $695M in future revenue.", "trigger" => "NIH budget announcement for FY2025; any public statement on PATH study contract option exercise"}